Biotechnology News and Research

RSS

Ranbaxy and Teva announce generic Lipitor agreement

Teva Pharmaceutical Industries Ltd. announced today that pursuant to an agreement between its subsidiary, Teva Pharmaceuticals USA, Inc. and Ranbaxy Laboratories Limited, a portion of the profits from Ranbaxy's sales of Atorvastatin Calcium Tablets during Ranbaxy's 180-day first-to-file exclusivity period, will be paid to Teva.

1 Dec 2011

Affymetrix signs definitive agreement to acquire eBioscience

Affymetrix, Inc., today announced that it has signed a definitive agreement to acquire eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics. Under the terms of the agreement, Affymetrix will acquire eBioscience for $330 million in cash subject to certain customary adjustments.

30 Nov 2011

Neogenix novel antibody selected as one of Windhover's 2011 Top 10 Projects to Watch

Neogenix Oncology, Inc. has announced that the company's novel antibody NEO-101, which targets pancreatic and colorectal cancer cells, has been selected as one of Windhover's 2011 Top 10 Projects to Watch.

30 Nov 2011

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced the company will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium December 6-10.

30 Nov 2011

Babraham Institute receives BBSRC grant to study effects of ageing on immune system

Efforts to understand the effect of ageing on the immune system received a boost today as the Biotechnology and Biological Sciences Research Council (BBSRC) announced investment in a new £3.6 million research project.

30 Nov 2011

Scientists regenerate functional muscle tissue in mice

A team of scientists from Worcester Polytechnic Institute (WPI) and CellThera, a private company located in WPI's Life Sciences and Bioengineering Center, have regenerated functional muscle tissue in mice, opening the door for a new clinical therapy to treat people who suffer major muscle trauma.

30 Nov 2011

Nanomedicine breakthrough by IBN and IBM named a ‘world changer’

A nanoparticle that can destroy drug-resistant bacteria developed by the Institute of Bioengineering and Nanotechnology (IBN), and the IBM Almaden Research Center, has recently been named one of 10 world changing ideas by Scientific American in its Technology Special Report ('World Changing Ideas – 10 New Technologies That Will Make a Difference', December 2011).

29 Nov 2011

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed patient enrollment in its Phase IIb study with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection.

29 Nov 2011

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Commission (EC) has extended the therapeutic indication for Soliris® (eculizumab) to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS).

29 Nov 2011

Largest survey on genetic, epigenetic stability of stem cells

An international study, published today in the prestigious journal Nature Biotechnology, reveals more about human pluripotent stem cells and their genetic stability and has important implications for the development of therapies using these cells.

29 Nov 2011

New research institute at The University of Texas MD Anderson Cancer Center

Academic and government leaders announced today the establishment of a major new research institute at The University of Texas MD Anderson Cancer Center that will blend the best attributes of academic and industrial research to identify and validate new cancer targets, convert such scientific knowledge into new cancer drugs, and advance these novel agents into innovative clinical trials.

29 Nov 2011

Selcia completes 14C radiolabelled API projects for clients

Selcia has successfully completed 14C radiolabelled API projects on behalf of a diverse range of clients for phase 1 human trials, following MHRA GMP Certification in September 2010. In response to a sharp increase in demand for this specialist service, Selcia has invested to double its capacity for handling GMP radiolabelling projects.

29 Nov 2011

New way of monitoring blood pressure wins innovation and technology award

Revolutionary device developed by University of Leicester, in collaboration with biotech SME HealthStats in Singapore and the NHS, wins Times Higher Education Award.

29 Nov 2011

Enrollment complete in SUSTAIN Phase 2b clinical trial for atherosclerotic CVD

Resverlogix Corp. today announced that SUSTAIN, a Phase 2b clinical trial comprised of 176 subjects, is fully enrolled.

28 Nov 2011

GVK Biosciences and Moulder Center at Temple University enter drug discovery alliance

GVK Biosciences, Asia's leading drug discovery research & development organization, announced today that it has entered into a drug discovery alliance with the Moulder Center for Drug Discovery Research at Temple University.

28 Nov 2011

Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Micromet, Inc. today announced that it has initiated a phase 2 trial of its lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

28 Nov 2011

Exelixis and NCI's CTEP enter CRADA to further evaluate cabozantinib

Exelixis, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) for further evaluation of cabozantinib, Exelixis' lead compound, in a variety of solid tumors.

28 Nov 2011

Roche NimbleGen, BGI develop Major Histocompatibility Complex region capture technology

Roche NimbleGen, Inc. and BGI, the world's largest genomic organization, announced that they have developed a Major Histocompatibility Complex (MHC) region capture technology based on NimbleGen SeqCap EZ Choice Library, a revolutionary process for the enrichment of the MHC region.

28 Nov 2011

Advaxis completes ADXS-HER2 pre-IND meeting with FDA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, completed a pre-IND meeting with the FDA on November 22, 2011 to discuss the development plan for ADXS-HER2, an immunotherapy for the treatment of HER2 expressing cancers.

23 Nov 2011

Live cell encapsulation technology helps overcome obstacles facing applications of live stem cell usage

Nuvilex, Inc. announced today testing confirmed that through use of live cell encapsulation technology, two major obstacles facing the vast and broad applications of live stem cell use have been overcome.

23 Nov 2011

Biotechnology News and Research

Ranbaxy and Teva announce generic Lipitor agreement

Affymetrix signs definitive agreement to acquire eBioscience

Neogenix novel antibody selected as one of Windhover's 2011 Top 10 Projects to Watch

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Babraham Institute receives BBSRC grant to study effects of ageing on immune system

Scientists regenerate functional muscle tissue in mice

Nanomedicine breakthrough by IBN and IBM named a ‘world changer’

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Largest survey on genetic, epigenetic stability of stem cells

New research institute at The University of Texas MD Anderson Cancer Center

Selcia completes 14C radiolabelled API projects for clients

New way of monitoring blood pressure wins innovation and technology award

Enrollment complete in SUSTAIN Phase 2b clinical trial for atherosclerotic CVD

GVK Biosciences and Moulder Center at Temple University enter drug discovery alliance

Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Exelixis and NCI's CTEP enter CRADA to further evaluate cabozantinib

Roche NimbleGen, BGI develop Major Histocompatibility Complex region capture technology

Advaxis completes ADXS-HER2 pre-IND meeting with FDA

Live cell encapsulation technology helps overcome obstacles facing applications of live stem cell usage

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News